Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
A medical trial led by train scientist Lee Jones, PhD, at Memorial Sloan Kettering Most cancers Heart means that particular quantities of endurance train...
Hope S. Rugo, MD, Winterhof Household Endowed Professorship in Breast Most cancers, director of Breast Oncology and Medical Trials Training at UCSF, discusses...
